Macrophage populations were skewed towards elevated numbers of pro-inflammatory HLA-DR + /CD163- M1 type macrophages upon osimertinib treatment in the PC9 parental tumor cohort (Fig. 5c, d, Supplementary Fig. 9b). This evidence concerns the gene CD163 and neoplasm.